Human cells, tissues, and cellular and tissue-based products (HCT/Ps) consist of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient. The Food and Drug Administration regulates a cellular therapy product solely as an HCT/P (i.e. "361 product") if it meets all the following criteria in 21 CFR 1271.10(a):
HCT/Ps are subject to the regulations in 21 CFR 1271 including establishment registration, donor eligibility (donor screening and testing), Current Good Tissue Practice (CGTP), additional regulatory requirements (adverse reaction reporting, HCT/P deviation reporting and labeling), and exemptions and alternative procedures. The regulatory requirements for allogeneic products are more extensive than for autologous products but, in general, FDA regulations emphasize preventing the risk of communicable disease transmission by HCT/Ps. Premarket review (licensure, clearance, and approval) by the FDA is not required for HCT/Ps.
Examples of HCT/Ps are listed below:
AABB's Standards for Blood Banks and Transfusion Services defines accreditation requirements for facilities involved in collecting, processing, distributing, and transfusing blood and blood components. Because blood centers and transfusion services may store and dispense tissues (i.e., bone, ligament, and skin), these products are addressed in the general quality system requirements of the AABB Standards. Although the FDA requires tissue banks to track tissues from the donor to the consignee (or final disposition), hospitals are considered exempt from this requirement. AABB and other standards and accreditation programs have been working to implement ISBT-128 labeling — a standardized system widely used in the blood banking, tissue and cellular therapies industries — to preserve the traceability of tissue products. Activities related to the preparation and dispensing of tissues and associated record-keeping requirements are addressed in AABB's Standards.
HPCs can be obtained from different sources (marrow, cord blood, peripheral blood) and are used in a variety of therapeutic applications. HPC from marrow is regulated by the Health Resources and Services Administration, and HPC from peripheral blood collected by apheresis is regulated as an HCT/P.
Effective Oct. 20, 2011, minimally manipulated HPCs sourced from placental/umbilical cord blood for unrelated allogeneic use require a biologics license application prior to marketing, or they must be distributed under an Investigational New Drug . Read more about how these HPC, Cord Blood products are regulated as biological products in addition to relevant HCT/P regulations.
February 24, 2021
February 23, 2021
February 23, 2021